Aprepitant (Emend, Merck and Co. Inc., Whitehouse Station, NJ, USA) is a potent antagonist of substance P/neurokinin-1 (NK1) receptors effective for treatment of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy regimens. Even though the role of aprepitant in the context of hematopoietic SCT (HSCT) has not been clearly defined, national antiemetic guidelines recommend addition of this drug to standard antiemetic regimens. 1, 2 Aprepitant is both a substrate and a moderate inhibitor of human cytochrome P450 (CYP450), specifically CYP3A4. Use of aprepitant in the context of SCT presents multiple opportunities for drug interactions. 3, 4 Sirolimus and tacrolimus are immunosuppressive agents used for prevention of GVHD 5, 6 that are also substrates for CYP3A4 isoenzyme and P-glycoprotein. 7, 8 Drugs known to inhibit CYP3A4, such as aprepitant, have the potential to increase the bioavailability of these two agents, leading to overt toxicity.
In this retrospective study, we present data on a consecutive case series of 85 patients (aprepitant group: n ¼ 14, control group: n ¼ 71) treated with a tacrolimus/sirolimusbased GVHD prophylactic regimen, some of whom also received aprepitant during conditioning for an allogeneic HSCT. Patients were transplanted between May 2008 and July 2009 at City of Hope. We explored the nature and significance of the potential drug-drug interactions between aprepitant and initial doses of tacrolimus/sirolimus.
Patients were included in the study if they underwent reduced-intensity HSCT from a sibling or a matched unrelated donor (MUD). All patients received a conditioning regimen of fludarabine 25 mg/m 2 daily for five days starting on day À9 and melphalan 140 mg/m 2 on day À4. The GVHD prophylaxis regimen consisted of sirolimus 12 mg orally on day À3 (loading dose), followed by 4 mg daily. Tacrolimus was administered initially as 0.02 mg/kg intravenously daily, starting on day À3. Both drugs were subsequently dose adjusted to maintain serum levels between 5-10 ng/mL or to mitigate toxicity. A select few patients undergoing MUD HSCT also received mini-MTX (14.3% in study group vs 15.5% in the control group) or antithymocyte globulin (7.1% in study group and 5.6% in the control arm).
The standard antiemetic regimen consisted of ondansetron (Zofran, GlaxoSmithKline, Philadelphia, PA, USA) 24 mg i.v. daily starting on day À4 for three days. Patients also received dexamethasone 10 mg and lorazepam 1 mg i.v.
prior to administration of melphalan on day À4. Oral aprepitant was administered as a three-day course of 125 mg on day 1 and 80 mg on days 2 and 3. The first dose of aprepitant was administered between days À4 and À2 of transplant in all patients. Patients Table 1 Patient, disease and treatment characteristics Descriptive statistics were used to summarize baseline characteristics. Fisher's exact test was used to examine possible differences in baseline characteristics and outcome data between the aprepitant group and control group, and Wilcoxon rank sum was used for analysis of continuous/ numeric data. The following end points were examined: sirolimus and tacrolimus serum drug levels (loading and median of first 30 days post HSCT), acute GVHD, thrombotic microangiopathy (TMA) and vital status.
Baseline patient characteristics were generally similar for the two cohorts (Table 1 ) with the exception of gender and baseline creatinine levels. The first set of tacrolimus and sirolimus levels were drawn one to three days after initiation of the immunosuppressive regimen (days À2 to 0 of HSCT). The median numbers of sampling points for tacrolimus/sirolimus levels over the first 30 days were 8.5/8.5 for the aprepitant group and 9/8 for the control group, respectively.
The post-loading sirolimus levels (drawn one to three days after loading dose) were significantly higher in the aprepitant group (29.2 vs 13.5 ng/mL, P ¼ 0.003, Table 2 ), while the levels were not different for tacrolimus (9.2 vs 8.6 ng/mL, P ¼ 0.13). There was a trend toward higher median tacrolimus levels over the first 30 days for the patients in the control group (8.2 vs 7.3 ng/mL, P ¼ 0.05). In response to elevated post-loading sirolimus levels clinicians drastically reduced the sirolimus dose, which led to subtherapeutic sirolimus levels (o5 ng/mL) in six patients in the aprepitant group.
All but five patients experienced neutrophil engraftment (ANC 4500) with a median time to engraftment of 14 days in both groups. There were no significant differences in the cumulative incidence of acute GVHD or 100-day survival (Table 2) . We observed no TMA in the aprepitant group.
Drug interactions may lead to overt toxicity/complications or treatment failure, especially in patients undergoing HSCT. Our data demonstrate the drug interaction between sirolimus and aprepitant, in which concomitant administration leads to a twofold increase in sirolimus levels. This observation was consistent with the fact that both drugs are substrates for CYP3A4. However, we did not observe any significant impact of coadministration of sirolimus and aprepitant on clinical outcomes such as survival, GVHD or TMA in this cohort. As we constantly adjust the drug doses according to the serum levels, the difference in sirolimus levels was not observed over the duration of first 30 days post HSCT.
We observed no significant differences in tacrolimus levels between the two groups. Although Ibrahim et al. 4 had reported previously that i.v. tacrolimus trough concentrations may be affected by aprepitant, the observed interaction was not clinically significant and most of the tacrolimus levels were within the therapeutic range.
While coadministration of sirolimus with strong inhibitors of CYP3A4 and/or P-glycoproteins is not recommended, recent studies have demonstrated that some of these agents, including azole antifungal agents may be administered concomitantly if careful monitoring and dose adjustment of sirolimus is employed. 9, 10 Our data must be interpreted with caution since the study was retrospective, with a small number of patients P-values are determined using Wilcoxon rank-sum tests.
Letter to the Editor analyzed. There are likely to be other factors not examined in this study that may exert an impact on the drug levels such as genetic variation in drug-metabolism genes including CYP3A4. In summary our data demonstrate the drug interaction between sirolimus and aprepitant, and strongly suggest that lowering the current 12 mg loading dose on day À3 should be considered, and that serum levels should be closely monitored.
